Oxitan Oxaliplatin represents a specialized cytotoxic chemotherapy medication containing oxaliplatin as its active pharmaceutical ingredient. This alkylating agent is specifically ...

Oxitan Oxaliplatin represents a specialized cytotoxic chemotherapy medication containing oxaliplatin as its active pharmaceutical ingredient. This alkylating agent is specifically formulated for treating metastatic colorectal cancer, operating through DNA cross-linking mechanisms that disrupt cancer cell replication. Available in precise 50mg and 100mg single-dose vials, the product ensures accurate dosing for medical practitioners while maintaining stability under proper storage conditions. Its standardized formulation supports consistent therapeutic outcomes in clinical environments where treatment protocols demand reliability and precision. The medication's quality-controlled production meets stringent pharmaceutical standards, making it a trusted option for healthcare providers managing complex oncology cases.

This pharmaceutical product serves primarily within hospital oncology departments, cancer treatment centers, and specialized clinics managing metastatic colorectal cancer. Medical oncologists incorporate Oxitan into combination chemotherapy regimens alongside other anticancer agents to enhance treatment efficacy for advanced gastrointestinal cancers. The drug finds application across both public healthcare institutions and private cancer facilities that adhere to strict chemotherapy administration protocols. Its usage extends to tertiary care hospitals where multidisciplinary teams manage aggressive cancers requiring coordinated treatment approaches. Oncology practitioners value its proven performance in treatment protocols where precision medicine and reliable therapeutic outcomes are essential for patient care.

Oxitan delivers significant value through its consistent quality and reliability within cancer treatment protocols, ensuring healthcare providers maintain uninterrupted treatment schedules. The product's standardized formulation and packaging simplify inventory management for hospital pharmacies and distributors, optimizing supply chain efficiency. Medical institutions benefit from its established efficacy in treating metastatic colorectal cancer, supporting positive patient outcomes through trusted therapeutic options. Manufacturers implement rigorous quality control throughout production, guaranteeing batch-to-batch consistency that medical professionals depend upon for critical treatments. This reliability translates into enhanced patient safety protocols and reduced treatment variability within clinical environments, ultimately supporting healthcare facilities in delivering effective cancer care.

Key Features:
- Contains oxaliplatin as the active pharmaceutical ingredient for targeted chemotherapy
- Available in precise 50mg and 100mg single-dose vial configurations
- Manufactured under strict pharmaceutical quality control standards
- Classified as a cytotoxic alkylating agent with DNA cross-linking mechanism
- Requires professional medical supervision for intravenous administration

Benefits:
- Provides reliable treatment option for metastatic colorectal cancer chemotherapy protocols
- Ensures consistent therapeutic performance through standardized formulation and dosing
- Supports clinical workflows with stable shelf life and proper storage characteristics
- Delivers proven efficacy in combination therapies for advanced gastrointestinal cancers
- Maintains batch-to-batch consistency through rigorous manufacturing quality controls